share_log

Eliem Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(5.85%),Deep Track Biotechnology Master Fund, Ltd.(5.85%), etc.

Eliem Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(5.85%),Deep Track Biotechnology Master Fund, Ltd.(5.85%), etc.

Eliem Therapeutics | SC 13G:超過5%持股股東披露文件-Deep Track Capital, LP(5.85%),Deep Track Biotechnology Master Fund, Ltd.(5.85%)等
美股SEC公告 ·  2024/07/02 16:09
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息